Pantoprazol Mepha (Pantoprazole Sodium)

Pantoprazole Sodium, the active ingredient in Pantoprazol Mepha, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazol Mepha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Mepha is a proton pump inhibitor that acts on the gastric acid secretion pathway. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Pantoprazol Mepha may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Severe hypersensitivity: rash, angioedema, anaphylaxis. - Liver enzyme elevation: potential hepatotoxicity. - Low magnesium (hypomagnesemia): may cause muscle cramps or arrhythmia.

When prescribing Pantoprazol Mepha, consider the following safety measures. - Renal impairment: adjust monitoring, as drug clearance may be reduced. - Hepatic impairment: use with caution; limited data in severe liver disease. - Long‑term use: monitor for vitamin B12 deficiency and bone density loss. - Pregnancy: only use if clearly needed after risk‑benefit assessment. - Breastfeeding: assess infant risk; benefits should outweigh potential exposure. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Mepha can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation. - Methotrexate: reduced renal clearance may raise toxicity risk. - Digoxin: slight increase in serum levels; observe for toxicity signs. - Clopidogrel: diminished antiplatelet effect; consider alternative therapy.